[go: up one dir, main page]

AU2018382586B2 - Recombinant IgG Fc multimers for the treatment of neuromyelitis optica - Google Patents

Recombinant IgG Fc multimers for the treatment of neuromyelitis optica Download PDF

Info

Publication number
AU2018382586B2
AU2018382586B2 AU2018382586A AU2018382586A AU2018382586B2 AU 2018382586 B2 AU2018382586 B2 AU 2018382586B2 AU 2018382586 A AU2018382586 A AU 2018382586A AU 2018382586 A AU2018382586 A AU 2018382586A AU 2018382586 B2 AU2018382586 B2 AU 2018382586B2
Authority
AU
Australia
Prior art keywords
val
pro
ser
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018382586A
Other languages
English (en)
Other versions
AU2018382586A1 (en
Inventor
Adriana BAZ MORELLI
Rolf SPIRIG
Lukmanee Tradtrantip
Alan Verkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Lengnau AG
University of California San Diego UCSD
Original Assignee
CSL Behring Lengnau AG
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG, University of California Berkeley, University of California San Diego UCSD filed Critical CSL Behring Lengnau AG
Publication of AU2018382586A1 publication Critical patent/AU2018382586A1/en
Application granted granted Critical
Publication of AU2018382586B2 publication Critical patent/AU2018382586B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018382586A 2017-12-14 2018-12-14 Recombinant IgG Fc multimers for the treatment of neuromyelitis optica Active AU2018382586B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598592P 2017-12-14 2017-12-14
US62/598,592 2017-12-14
EP18168448 2018-04-20
EP18168448.1 2018-04-20
PCT/EP2018/084894 WO2019115745A1 (fr) 2017-12-14 2018-12-14 Multimères d'igg fc recombinants pour le traitement de la neuromyélite optique

Publications (2)

Publication Number Publication Date
AU2018382586A1 AU2018382586A1 (en) 2020-07-02
AU2018382586B2 true AU2018382586B2 (en) 2025-01-16

Family

ID=64949238

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018382586A Active AU2018382586B2 (en) 2017-12-14 2018-12-14 Recombinant IgG Fc multimers for the treatment of neuromyelitis optica

Country Status (9)

Country Link
US (1) US20210095006A1 (fr)
EP (1) EP3723791B1 (fr)
JP (1) JP7351835B2 (fr)
CN (1) CN112004550A (fr)
AU (1) AU2018382586B2 (fr)
CA (1) CA3085385A1 (fr)
DK (1) DK3723791T3 (fr)
ES (1) ES2975776T3 (fr)
WO (1) WO2019115745A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10373019B2 (en) * 2016-01-13 2019-08-06 Ford Global Technologies, Llc Low- and high-fidelity classifiers applied to road-scene images
EP4028415A1 (fr) * 2019-09-13 2022-07-20 CSL Behring Lengnau AG Multimères fc d'igg recombinants pour le traitement de troubles rénaux médiés par des complexes immuns
CN114894911B (zh) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 一种控制牛血清产品质量方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139365A1 (fr) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Protéines fc polymères et procédés de criblage pour modifier leurs caractéristiques fonctionnelles
WO2017129737A1 (fr) * 2016-01-27 2017-08-03 Csl Behring Recombinant Facility Ag Multimères fc d'igg recombinants

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2008151088A2 (fr) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Agents de liaison de récepteur fc de région constante d'immunoglobuline
EP2598533B1 (fr) 2010-07-28 2019-02-20 Gliknik Inc. Protéines de fusion de fragments de protéines humaines naturelles pour créer des compositions de fc d'immunoglobuline multimérisé de façon ordonnée
CN104870055A (zh) 2012-10-17 2015-08-26 利物浦热带医学院 免疫调节蛋白
TW201619188A (zh) * 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
WO2015132365A1 (fr) * 2014-03-05 2015-09-11 Ucb Biopharma Sprl Protéines fc multimères
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
EP3436484B1 (fr) 2016-03-30 2025-10-01 AB Biosciences, Inc. Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139365A1 (fr) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Protéines fc polymères et procédés de criblage pour modifier leurs caractéristiques fonctionnelles
WO2017129737A1 (fr) * 2016-01-27 2017-08-03 Csl Behring Recombinant Facility Ag Multimères fc d'igg recombinants

Also Published As

Publication number Publication date
ES2975776T3 (es) 2024-07-15
JP7351835B2 (ja) 2023-09-27
CN112004550A (zh) 2020-11-27
WO2019115745A1 (fr) 2019-06-20
CA3085385A1 (fr) 2019-06-20
EP3723791B1 (fr) 2024-02-21
US20210095006A1 (en) 2021-04-01
EP3723791A1 (fr) 2020-10-21
JP2021506772A (ja) 2021-02-22
AU2018382586A1 (en) 2020-07-02
DK3723791T3 (da) 2024-04-08

Similar Documents

Publication Publication Date Title
JP6906882B2 (ja) 第ｖｉｉｉ因子キメラタンパク質及びその使用
JP7022165B2 (ja) ＸＴＥＮおよびｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
KR102756547B1 (ko) 세르핀 융합 폴리펩타이드 및 이의 이용 방법
JP2022089920A (ja) 最適化第ｖｉｉｉ因子遺伝子
US20190119377A1 (en) Recombinant igg fc multimers
TW202003554A (zh) 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP7074792B2 (ja) ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質
AU2019204448B2 (en) UTI fusion proteins
AU2018382586B2 (en) Recombinant IgG Fc multimers for the treatment of neuromyelitis optica
HK40037563B (en) Recombinant igg fc multimers for the treatment of neuromyelitis optica
HK40037563A (en) Recombinant igg fc multimers for the treatment of neuromyelitis optica
US20220332847A1 (en) RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)